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untington disease (HD) is characterized by the
preferential loss of striatal medium-sized spiny
neurons (MSNs) in the brain. Because MSNs re-
ceive abundant glutamatergic input, their vulnerability to
excitotoxicity may be largely inﬂuenced by the capacity
of glial cells to remove extracellular glutamate. However,
little is known about the role of glia in HD neuropathol-
ogy. Here, we report that mutant huntingtin accumulates
in glial nuclei in HD brains and decreases the expression
of glutamate transporters. As a result, mutant huntingtin
H
 
(htt) reduces glutamate uptake in cultured astrocytes and
HD mouse brains. In a neuron–glia coculture system,
wild-type glial cells protected neurons against mutant htt-
mediated neurotoxicity, whereas glial cells expressing
mutant htt increased neuronal vulnerability. Mutant htt in
cultured astrocytes decreased their protection of neurons
against glutamate excitotoxicity. These ﬁndings suggest
that decreased glutamate uptake caused by glial mutant htt
may critically contribute to neuronal excitotoxicity in HD.
 
Introduction
 
Expansion of a polyglutamine (PolyQ) tract in huntingtin (htt)
causes the preferential degeneration of striatal neurons in pa-
tients with Huntington’s disease (HD) despite the widespread
expression of htt in neuronal and nonneuronal cells. The fact
that HD transgenic mouse models can develop neurological
symptoms without obvious neurodegeneration indicates that
early neuronal injury and dysfunction are the major causes of
neuropathologic phenotypes in these mice. Consistently, early
neuronal injury caused by mutant htt can lead to reactive glio-
sis in many HD mouse models (Reddy et al., 1998; Lin et al.,
2001; Yu et al., 2003) and in postmortem brains of HD patients
(Myers et al., 1991; Sapp et al., 2001). Recent studies show that
transgenic mice expressing mutant htt only in cortical neurons
do not have obvious gliosis and other pathologies, suggesting
that cell–cell interactions play a critical role in HD pathology
(Gu et al., 2005). However, little is known about the role of glia
htt in HD neuropathology, despite findings that htt is also ex-
pressed in glial cells (Singhrao et al., 1998; Hebb et al., 1999).
Glial cells constitute 90% of the cells in the brain and
provide neurons with nutrition, growth factors, and structural
support. They also protect against excitotoxicity by clearing
excess excitatory neurotransmitters from the extracellular
space (Maragakis and Rothstein, 2001). This protective func-
tion may be particularly relevant to the selective degeneration
of medium-sized spiny neurons (MSNs) in the striatum in HD
and the theory of excitotoxicity for HD pathogenesis (Coyle
and Schwarcz, 1976; Beal, 1994). MSNs are innervated by
glutamatergic axons, and overstimulation of glutamate recep-
tors induces cell death or excitotoxicity. The involvement of
excitotoxicity in HD is supported by considerable evidence.
First, administration of NMDA receptor agonists to the stria-
tum of normal animals causes a selective loss of MSNs and
neurological symptoms similar to those seen in HD patients
(Coyle and Schwarcz, 1976). Second, NMDA receptor antago-
nists effectively reduce excitotoxicity in HD animal models
(Greene et al., 1993). Furthermore, HD transgenic mouse
models show increased NMDA receptor activity in neurons
(Cepeda et al., 2001; Zeron et al., 2002). The abundant
glutamatergic afferents to MSNs and the unique NMDA re-
ceptor subunit composition in MSNs (Calabresi et al., 1998;
Kuppenbender et al., 2000; Li et al., 2003) may confer their
preferential vulnerability in HD, especially when the glutamater-
gic input is increased or the clearance of extracellular glutamate
is decreased. 
Clearance of extracellular excitatory neurotransmitters
is largely performed by glutamate transporters (GLT-1 and
GLAST) in astrocytes, which is the major subtype of glia
(Maragakis and Rothstein, 2001). It has been found that mutant
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htt can reduce the expression level of glutamate transporter-1
(GLT-1) in the brains of HD transgenic mice and 
 
Drosophila
melanogaster 
 
(Lievens et al., 2001, 2005; Behrens et al., 2002).
It remains unclear whether mutant htt directly affects glial
function and, more important, how glial dysfunction contrib-
utes to neuropathology. The present study provides evidence
that NH
 
2
 
-terminal mutant htt in glial cells reduces glial glu-
tamate uptake, and this glial dysfunction may critically contrib-
ute to neuronal excitotoxicity. 
 
Results
 
Intranuclear htt aggregates in glial cells 
 
We used an antibody (EM48) to htt and performed immunogold
labeling to examine brains from R6/2 mice that express HD
exon1 protein with a 115–150-glutamine repeat. EM48 sensi-
tively detects aggregated htt in HD brain (Li et al., 2000), en-
abling us to identify htt nuclear aggregates in glial cells in the
striatum of R6/2 mice (Fig. 1 A). Glia can be classified as mi-
croglia, astrocytes, or oligodendrocytes. They are distinguished
from neurons by a condensed nuclear envelope, a small and ir-
regular shape, and a limited cytoplasmic area with sparse con-
tent. Microglial cells often show highly condensed nuclear
membranes. Identification of astrocytes is primarily based on
the presence of fibrils within their processes, and oligodendro-
cytes are often recognized by their association with groups of
myelinated nerve fibers. The ultrathin sections used for elec-
tron microscopy might not have allowed us to definitively
identify astrocytes containing htt aggregates, as a single plane
of an ultrathin section could have been too thin to show both htt
aggregates and the distinguishing morphological features of the
cell. However, some glial cells, which displayed a highly con-
densed nuclear membrane and a small cytoplasmic space, con-
tained intranuclear aggregates (Fig. 1, A–C). The nuclear htt
aggregates in these glial cells are clearly smaller than neuronal
nuclear inclusions (Fig. 1 D). Small glial nuclear inclusions
were observed in the striatum (Fig. 1 A) and cortex (Fig. 1, B
and C) of R6/2 mice 11–12 wk old. We also observed some hy-
pertrophic and dark glial cells with increased electron density
in R6/2 mice. These cells did not show visible cytoplasmic or-
ganelles and, in many cases, engulfed neuronal bodies or pro-
cesses (Fig. S1, A and B, available at http://www.jcb.org/cgi/
content/full/jcb.200508072/DC1). The hypertrophic glial cells
are smaller and darker than the previously identified dark neu-
rons (Turmaine et al., 2000; Yu et al., 2003), which often have
long neuronal processes that have begun to degenerate (Fig.
S1, C and D). Like dark neurons, the degenerating glial cells
were not frequently observed and did not show htt aggregates,
suggesting that glial dysfunction rather than degeneration is
more important for HD pathology.
 
Expression of mutant htt in astrocytes 
in HD transgenic mouse brains
 
Because the spectrum of morphological variations among glial
cells makes it difficult to define astrocytes containing htt ag-
gregates by electron microscopy, we performed immunofluo-
rescent double labeling on thin sections (8–10 
 
 
 
m) of frozen
brain. We first examined white matter that was enriched in as-
trocytes and was devoid of neurons. Astrocytes are the most
abundant glial cell type in the brain and can be specifically la-
beled by antibody to glial fibrillary acidic protein (GFAP).
Although GFAP-labeling was prominent in white matter, only
a few cells displayed both strong GFAP staining and mutant htt
(Fig. 2 A). This is perhaps because strong GFAP staining is
only seen in reactive astrocytes that may have an increased ca-
pacity to clear mutant htt. We also performed confocal imaging
analysis of white matter and confirmed that mutant htt forms
small aggregates in GFAP-positive glial cells (Fig. 2 B). In ad-
dition, groups of GFAP-positive astrocytes were often found in
the striatum (Fig. 2 C) and were not labeled by antibodies to
other glial markers (myelin basic protein for oligodendrocytes
and F4/80 for microglia) or the neuronal marker NeuN (not de-
picted), suggesting that they are mainly astrocytes. Glial nuclei,
when stained with the Hoechst dye, are smaller and denser than
neuronal nuclei. The small htt aggregates in glial nuclei as well
as GFAP staining of glial processes allowed us to distinguish
htt-containing glial cells from neurons that show larger and
more intense EM48-labeled aggregates in their nuclei (Fig. 2, A
and C). Based on these characteristics, we counted htt-containing
glial cells in the HD mouse brains.
Unlike neurons, only some glial cells show intranuclear htt
labeling, but the prevalence of nuclear htt aggregates in glial
cells is increased with age (Fig. 2 C). In the striatum, 17.6% of
glial cells showed intranuclear htt staining at 4–5 wk, whereas
42 and 52.6% of glial cells displayed nuclear htt at 8–9 and 11–
12 wk, respectively (Fig. 2 D). We also used an antibody to an-
other glial marker, glutamate/aspartate transporter (GLAST),
and validated the above finding (unpublished data). Because
EM48 is sensitive to aggregated htt and might not label soluble
mutant htt, the number of glia expressing mutant htt might be
more than what we observed. The progressive increase of glial
nuclear htt correlates with disease progression in R6/2 mice,
which show significant neurological symptoms at 8 wk and
often die after 12 wk (Davies et al., 1997). In white matter, a
Figure 1. Electron micrographs of HD mouse brains. (A–D) EM48 immu-
nogold labeling of the striatum (A) and cortex (B–D) of R6/2 mice at 12 wk
of age. Immunogold-labeled aggregates are present in glial cells (arrows),
which show a more condensed nuclear membrane and a smaller sized
cytoplasm than do neuronal cells (arrowheads). Bars, 1  m. 
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similar age-dependent increase of intranuclear htt was also seen
(Fig. S2, available at http://www.jcb.org/cgi/content/full/jcb.
200508072/DC1). Glial htt aggregates seem to be slightly more
abundant in the striatum than in the cortex, hippocampus, and
white matter (Fig. 2 E), perhaps because of the relatively high
density of astrocytes in the striatum (San Jose et al., 2001).
However, the accumulation of htt in glial nuclei occurs notice-
ably later than in neurons (Fig. 2 C), suggesting that glial cells
are more capable of clearing misfolded htt than neuronal cells. 
 
Decreased expression of GLT-1 and 
glutamate uptake in HD mouse brains
 
Decreased expression of GLT-1 protein was observed in the HD
brain by Western blotting (Fig. 3, A and B). The expression of
GLT-1 seems to correlate inversely with the age-dependent nu-
clear accumulation of htt in glial cells, as the brain of HD mice
at 11–12 wk showed a greater reduction of GLT-1 than those at
4 wk (Fig. 3, A and B). The expression level of GLAST ap-
peared to be variable in individual mice, but was not signifi-
cantly decreased in R6/2 mice as compared with littermate con-
trols (Fig. S3, A and B, available at http://www.jcb.org/cgi/
content/full/jcb.200508072/DC1). Although 
 
Hdh
 
 CAG knock-
in mice did not show a significant reduction of brain GLT-1 and
GLAST even at the age of 9 mo, a slight decrease of GLT-1 ex-
pression was observed in the striatum (Fig. S3, C and D). This
finding supports the idea that NH
 
2
 
-terminal mutant htt is more
toxic than full-length htt in affecting the expression of GLT-1.
Consistent with previous studies (Lievens et al., 2001; Behrens
et al., 2002), RT-PCR confirmed that GLT-1 transcripts were
significantly reduced in HD mouse brains, while GLAST tran-
scripts were slightly decreased (Fig. 3 C).
An interesting question is whether decreased glutamate
transporters can alter glutamate uptake in astrocytes. The activ-
ity of GLT-1 in astrocytes can be specifically inhibited by di-
hydrokainate (DHK; Kawahara et al., 2002). Although GLT-1
is present in some neurons under certain conditions (Mennerick
et al., 1998), a previous study using isolated synaptosomes to
examine glutamate uptake into neuronal vesicles did not find a
significant difference in DHK-specific glutamate uptake be-
tween R6/2 and wild-type mouse brains (Lievens et al., 2001).
We decided to use brain slices containing the cortex and stria-
tum to measure their uptake of [
 
3
 
H]glutamate, as the neuron–
glia interactions remain intact but the glutamate uptake into
astrocytes can be measured with DHK in this assay. Consistent
with the age-dependent decrease in the expression of GLT-1 in
HD mouse brains, DHK-specific glutamate uptake was more
significantly affected in slices from older R6/2 mice (Fig. 3 D),
demonstrating a close association between GLT-1 expression
and glutamate uptake in HD brain. 
 
Expression of mutant htt in cultured 
astrocytes from HD mouse brains 
 
Cell culture provides a good system to validate the specific
effect of mutant htt on glia. As expected, cultured GFAP-positive
astrocytes from R6/2 mice showed intranuclear htt aggregates
(Fig. 4 A). Only a fraction of these nuclear aggregates were
ubiquitinated (Fig. 4 B), and the formation of these nuclear htt
aggregates increased with culturing time (Fig. 4 C). The cells
containing htt aggregates were not labeled by antibodies to
markers of microglia and oligodendrocytes (not depicted), sug-
gesting that NH
 
2
 
-terminal mutant htt forms aggregates more
readily in astrocytic nuclei.
Figure 2.  Immunofluorescent labeling of htt-
containing glia in R6/2 transgenic mouse brains.
(A) Immunofluorescent labeling of brain sections
containing white matter (WM) and the central
region of the cerebellar cortex (Ctx) in an R6/2
mouse 8 wk old. Mouse antibody to GFAP la-
beled astrocytes (green) and rabbit EM48 la-
beled mutant htt (red). The nuclei were labeled
with Hoechst dye (blue). (B) Confocal imaging of
white matter showing that the nuclei of GFAP-
positive glial cells contain htt aggregates
(Video 1, available at http://www.jcb.org/
cgi/content/full/jcb.200508072/DC1). (C)
The striatal section of an R6/2 mouse at 8 wk of
age was stained with antibody to GFAP and the
nuclear dye Hoechst (top). EM48 immunostain-
ing for htt and merged image are also presented
(middle). Bottom panels shows merged images
of striatal regions from 12- or 4-wk old R6/2
mice. Arrows indicate glial nuclei that contain
EM48 staining. Small puncta represent neuropil
aggregates. (D) The percentage of glial cells
containing nuclear EM48 staining in the brain
striatal sections of R6/2 mice at the age of 4, 8,
or 12 wk. (E) The percentage of glial cells with
intranuclear htt in the striatum (Str), cortex (Ctx),
hippocampus (Hipp), and WM in R6/2 mice at
the age of 8–10 wk. The data (mean   SD)
were obtained from three to five mice per group.
**, P   0.01 compared with the samples of 8
or 12 wk old R6/2 mice. Bars: (A) 5  m; (B)
2.5  m; (C)10  m. 
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To examine whether glial cells expressing full-length
mutant htt also display nuclear aggregates, we cultured glial
cells from the brain of 
 
Hdh
 
 CAG(150) knock-in mice that do
not show obvious neuropathology and symptoms but have an
age-dependent accumulation of NH
 
2
 
-terminal htt in the nuclei
of some neurons (Lin et al., 2001). Western blotting verified
that NH
 
2
 
-terminal htt fragments were generated in cultured
knock-in astrocytes (Fig. 4 D). Some astrocytes contained
small aggregates in their nuclei (Fig. 4 E) after 3–4 wk in cul-
ture, but relative to R6/2 glial cells, the number of astrocytes
containing nuclear aggregates was considerably lower. An anti-
body (EM121) to the middle region of htt (amino acids 342–456)
did not reveal nuclear htt aggregates in knock-in astrocytes
(unpublished  data). This is consistent with the fact that the
cleavage of full-length mutant htt into small NH
 
2
 
-terminal mu-
tant htt fragments and the accumulation of these fragments are
required for the formation of nuclear aggregates (DiFiglia et
al., 1997; Li et al., 2000). 
 
Expression of htt in glial nuclei of HD 
knock-in mouse and patient brains
 
Examination of the striatum of 
 
Hdh
 
 CAG(150) knock-in mice
at 14–18 mo of age revealed EM48 labeling in the small and
dense nuclei of some GFAP-positive glial cells as compared
with intense EM48 labeling in large neuronal nuclei (Fig. 5 A).
The presence of mutant htt in glial nuclei was confirmed by
both conventional microscopy (Fig. 5 A) and confocal imaging
(Fig. 5 B) of white matter, which clearly showed that some
GFAP-positive glial nuclei contained small htt aggregates.
Younger 
 
Hdh
 
 CAG(150) knock-in mice (
 
 
 
9 mo) were not
found to have obvious EM48 staining in glial nuclei (unpub-
Figure 3.  Decreased expression of glutamate transporter GLT-1 and
glutamate uptake in HD mouse brain. (A and B) Western blot analysis of
the expression of GLT-1 in brain regions of wild-type (W1-W4) or R6/2
(HD1-HD4) mice at 4 wk (A) and 11–12 wk old (B). The same blots were
probed with antibody to tubulin. The signal ratios of GLT-1 to tubulin are
shown in the right. (C) RT-PCR analysis of the expression of GLT-1 and
GLAST in R6/2 (HD) and wild-type (WT) mouse brain cortex. Transcripts
for GLAST and actin were amplified in the same reaction (21 cycles), and
the same amounts of cDNA were used for GLT-1 PCR (23 cycles). The ra-
tios (mean   SEM, n   3) of GLT-1 (*, P   0.0079, WT vs. HD) and
GLAST (P   0.11, WT vs. HD) to actin were obtained with densitometry.
Panel C is the control RT-PCR without reverse transcriptase. (D) GLT-1–
specific glutamate uptake in brain slices of littermate control (WT) and
R6/2 (HD) mice at the age of 4–5 and 10–12 wk was obtained with DHK
(1 mM) treatment. Data are presented as mean   SEM (n    4 each
group). *, P   0.05; **, P   0.01 compared with WT control.
Figure 4. Age-dependent nuclear accumulation of mutant htt in cultured
glial cells. (A) Immunofluorescence double labeling showing that GFAP
(green) positive astrocytes display htt aggregates (red) in the nuclei of R6/2
glial cells. (B) Some intranuclear htt aggregates are also labeled by anti-
body to ubiquitin. (C) Immunofluorescent images of cultured glial cells that
were cultured for 2 and 12 wk showing the increase of glial htt aggregates
with time. (D) Western blotting of cultured astrocytes that were isolated
from the cortex of postnatal Hdh CAG(150) knock-in (KI) and littermate
control (WT) mice and had been cultured for 4 wk. The blot was probed
with antitubulin (bottom) and 1C2 (top), an antibody that is specific to ex-
panded polyQ tracts and reacts with NH2-terminal htt fragments containing
150Q. Arrow indicates full-length mutant htt. (E) Immunofluorescent images
of glial culture from Hdh CAG KI. GFAP (green) positive astrocytes (arrows)
contain intranuclear htt (red) aggregates. Some GFAP-negative cells (arrow-
head) also show intranuclear htt, suggesting that they might be immature
astrocytes or other types of cells. Bars, 5  m. 
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lished data). suggesting that the nuclear accumulation of mu-
tant htt in glia is age dependent. A previous study reported that
mutant htt is present in astrocytes of HD patient brains (Singhrao
et al., 1998). We also examined postmortem brains from late
stage (grade-3) HD patients and confirmed the expression of
mutant htt in HD brains by Western blotting (Fig. 5 C). Despite
severe degeneration in grade-3 HD brains, some GFAP-positive
glial cells still remained in these brains. Small EM48-labeled
aggregates (
 
 
 
0.3 
 
 
 
m) were seen in white matter and were
much smaller than neuronal nuclear aggregates that often ex-
ceeded 1.5 
 
 
 
m and were intensively labeled by EM48 (Fig. 5 D).
Immunofluorescent double labeling verified that the nuclei of
GFAP-positive glial cells contained EM48 immunoreactive ag-
gregates in HD patient brains (Fig. 5 E), which are similar in
size to those in glial cells in 
 
Hdh
 
 CAG(150) knock-in mice
(Fig. 5, A and B) and did not occur in the brain of Alzheimer’s
disease (AD) patient (Fig. 5 E). We observed that 
 
 
 
12.3%
of GFAP-positive cells contained htt aggregates. Given that
EM48 preferentially reacts with aggregated htt and that grade-3
HD brains might have lost some glial cells or their markers, the
number of glial cells expressing mutant htt, especially soluble
htt, is likely to be higher.
 
Expression of htt in cultured astrocytes 
by adenoviral infection
 
To identify the pathological changes that are specifically asso-
ciated with an expanded repeat, we infected glial cells with ad-
enoviral vectors expressing GFP fusion protein containing the
first 208 amino acids of human htt with 23Q (htt-23Q) or 130Q
(htt-130Q). Htt-23Q was predominantly diffuse in the cyto-
plasm, though its overexpression resulted in small puncta or
aggregates in the cytoplasm but not in the nucleus. However,
expanded polyQ caused htt-130Q to form significantly larger
and more abundant inclusions in both the cytoplasm and nucleus
(Fig. 6 A). Also, nuclear accumulation and aggregation of htt-
130Q were elevated by treatment with the proteasome inhibitor
 
N
 
-acetyl-leucinal-leucinal-norleucinal (Fig. 6 B, ALLN). All of
Figure 5. Expression of mutant htt in the brains of Hdh CAG(150) knock-
in mice and HD patient. (A) Immunofluorescent double labeling of the stri-
atum of heterozygous Hdh CAG(150) knock-in mice at 14–18 mo old.
Arrows indicates the nuclei (blue) of GFAP (green)-positive glial cells con-
taining EM48 labeling (red), and arrowhead indicates a neuronal nucleus,
which shows more intense EM48 labeling. (B) High magnification graphs
of confocal images of white matter of heterozygous Hdh CAG(150)
knock-in mice. Arrows indicate glial nuclei (blue) containing EM48 label-
ing (red). (C) Western blotting of caudate-putamen tissues from HD and
Alzheimer’s disease (AD; Control) patients. The blot was probed with anti-
actin (bottom) and 1C2 antibody (top). (D) Light microscopic graphs of
glial cells (arrows in upper panel) in white matter and neurons in the cortex
(bottom) in the EM48 stained HD brain sections. (E) Immunofluorescent
double labeling of white matter of HD patient brain with rabbit anti-htt
(EM48) and mouse anti-GFAP. Mutant htt (red) forms aggregates (arrow)
in the nucleus (blue) of an astrocytic cell that shows intense GFAP staining
(green) in its processes. The control is the AD brain section. Bars, 2  m.
Figure 6.  PolyQ-mediated intranuclear htt accumulation in glial cells.
(A) Immunofluorescent images of adenovirus-infected astrocytes that express
GFP-htt containing a 23- (23Q) or 130- (130Q) glutamine repeat. Immuno-
staining with EM48 confirms that htt-130Q is located in the nucleus and
forms nuclear aggregates. Nuclei are stained with Hoechst. (B) Proteasomal
inhibition by ALLN (10  g/ml) for 5 d significantly increases the formation
of nuclear aggregates of htt-130Q, but not htt-23Q, in infected glial cells.
(C) MTT assay of cultured glial cells infected by adenoviral-GFP ( GFP),
htt-23Q ( 23Q), or htt-130Q ( 130Q) for 9 d. (D) MTT assay of astro-
cytes from R6/2 mice (HD) or littermate controls (WT) cultured for 6 or 8 wk.
The data are presented as mean   SEM (n   3–4) and p values for 6- and
8-wk group comparisons (WT vs. HD) are 0.23 and 0.014, respectively.
Bars, 5  m. 
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these results indicate a specific nuclear accumulation of htt me-
diated by a large polyQ tract.
Adenoviral infection resulted in 
 
 
 
80% of cultured glial
cells expressing mutant htt. Unlike cultured neuronal cells in
which NH
 
2
 
-terminal mutant htt can cause nuclear or neuritic
fragmentation (Saudou et al., 1998; Li et al., 2000), htt-contain-
ing glial cells did not show obvious changes in their morphol-
ogy at different times after viral infection. We then examined
the viability of cultured glial cells using 3-(4,5-dimethyl thia-
zol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays.
Interestingly, astrocytes infected with either htt-23Q or htt-
130Q and HD astrocytes from R6/2 mice showed an increase in
MTT value (Fig. 6, C and D). Reactive astrocytes often have
activated proliferation and increased mitochondrial respiration,
which are reflected by increased MTT values (Setkowicz and
Janeczko, 1998; Norton, 1999). Overexpressed or misfolded
polyQ proteins might induce reactive astrocytes, resulting in
increased proliferation and mitochondrial respiration that lead
to a high MTT value. Although electron microscopy revealed
degenerated glia in HD mouse brain, this glial pathology may
occur in vivo or result from neuronal injury. We could not find
any evidence that mutant htt directly kills cultured glial cells in
vitro, even in the presence of cocultured neurons (unpublished
data), suggesting that mutant htt is more likely to cause glial
dysfunction rather than degeneration. 
 
Decreased expression of glutamate 
transporters in astrocytes expressing 
mutant htt
 
Next, we examined whether mutant htt in astrocytes directly af-
fects the expression of glutamate transporters. Western blots
revealed that the basal level of GLT-1 was lower in cultured as-
trocytes from R6/2 mouse brains than those from littermate
controls (Fig. 7 A), whereas the basal level of GFAP did not
differ. We then treated the astrocytes with dibutyryl cyclic
adenosine monophosphate (dBcAMP), which can significantly
increase the expression of GLT-1 by regulating its transcription
(Eng et al., 1997). The difference in the expression of GLT-1,
but not GFAP, between control and R6/2 astrocytes was en-
hanced by dBcAMP treatment (Fig. 7, A and B), suggesting
that mutant htt negatively affects gene transcription of GLT-1.
The expression of GLAST in HD glial cells and its up-regula-
tion by dBcAMP were also reduced as compared with wild-
type cells (Fig. 7, A and B), but this reduction was not as great
as the change in GLT-1. Because GLAST expression is not sig-
nificantly decreased in HD brains (Lievens et al., 2001; Behrens
et al., 2002), in vivo neuron–glia interactions may attenuate the
inhibitory effect of mutant htt on the protein expression of
GLAST in the brain.
To examine whether the decreased expression of GLT-1
is associated with expanded polyQ and also occurred in the
presence of neurons, we cultured adenovirus–htt–infected glial
cells with cortical or striatal neurons. Aggregated htt was seen
in htt-130Q–infected glial cells in EM48 Western blots (Fig. 7 D).
Because EM48 preferentially reacts with mutant and aggregated
htt (Li et al., 2000), htt-130Q and htt-20Q might be expressed
at a similar level. GLT-1, but not tubulin, was significantly
reduced in htt-130Q infected glial cells. Densitometry analysis
confirmed that this decrease was associated with expanded
polyQ  (unpublished data). Furthermore, htt-130Q infected
Figure 7. Decreased expression of GLT-1 in glial cells expressing mutant
htt. (A and B) Western blots of cultured astrocytes from R6/2 (HD) and
littermate control (WT) mice. Astrocytes that had been cultured 4–6 wk
and treated with ( ) or without (–) 0.25 mM dBcAMP were examined by
Western blotting with antibodies to GFAP and GLT-1. The same blots were
also probed with an antibody to tubulin. Two blots (a, b) containing differ-
ent cell samples are presented. (C) Densitometric analysis of signals of
immunoreactive bands. The ratios (mean   SEM, n   3–4) of GLAST (*,
P   0.045, WT vs. HD), GLT-1 (*, P   0.013; **, P   0.001 WT vs.
HD), and GFAP to tubulin. (D) Western blot analysis of the expression of
htt-23Q and htt-130Q in adenovirus-infected glial cells. Bracket indicates
the stacking gel in which aggregated htt-130Q is present. GLT-1 expres-
sion is reduced in htt-130Q astrocytes cocultured with cortical or striatal
neurons. (E) [
3H]Glutamate uptake assays of astrocytes infected with htt-
23Q or htt-130Q. Note that the glutamate uptake in htt-130Q–infected
cells is lower than in htt-23Q infected cells. The data are presented as
mean   SEM (*, P   0.05; **, P   0.01). The Vmax of [
3H]glutamate up-
take in htt-23Q and htt-130Q infected cells was 11.1   0.84 and 7.3  
1.21 nmol/min/mg protein, respectively. There was no significant differ-
ence in the apparent glutamate Kms (37.7   3.24 and 38.6   6.3 for
htt-23Q and htt-130Q, respectively).  
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astrocytes showed a significant reduction in uptake of [
 
3
 
H]
glutamate as compared with htt-23Q astrocytes (Fig. 7 E).
Because the Vmax, but not the Km, of [
 
3
 
H]glutamate uptake
was decreased in htt-130Q astrocytes (Fig. 7 E), expanded
polyQ appears to reduce the number of glutamate transporters
in these glial cells. This finding is consistent with the de-
creased expression of GLT-1 and GLAST in cultured R6/2
glial cells. 
 
Protection against htt-mediated 
neuronal toxicity by glial cells
 
To determine whether glia can protect against neuronal htt
cytotoxicity, we infected cultured neurons with adenoviral
GFP, htt-23Q, and htt-130Q constructs, and then cocultured
them with wild-type astrocytes. In the absence of glial cells,
htt-130Q neurons generally showed a decrease in the staining
of microtubule-associated protein 2 (MAP2) (Fig. 8 A), a neu-
ron-specific protein whose decrease reflects early neurodegen-
eration (Matesic and Lin, 1994). When htt-130Q neurons were
cocultured with wild-type glial cells, the number of MAP2-
positive neurons was significantly increased (Fig. 8 B). The
NMDA receptor blocker MK801 (dizocilpine maleate), which
increases the survival of cultured neurons (Driscoll et al.,
1991), also increased the number of MAP2-positive neurons
expressing htt-130Q (Fig. 8 B).
 
Glial htt promotes neuronal vulnerability
 
The preceding experiments examined glial protection for neu-
rons in which mutant htt was overexpressed. Overexpressed
mutant htt in neurons activates NMDA receptors and triggers
many other pathological pathways, such as caspase cascades
(Cepeda et al., 2001; Zeron et al., 2002; Li and Li, 2004), which
could counteract glial protection. Thus, a more important issue
is whether mutant htt, when expressed in glia, can reduce their
ability to protect neurons. To address this issue, we placed wild-
type neurons on glia that had been infected with adenoviral htt.
After 
 
 
 
3–4 wk in culture, astrocytes displayed larger nuclei
than neuronal nuclei and lacked MAP2 immunostaining, allow-
ing us to definitively distinguish them from neurons in the co-
culture. We did not observe a significant change in neuronal
morphology after coculturing with adenoviral htt-infected astro-
cytes for 4–5 d. However, after 
 
 
 
7–8 d, a significant decrease
in the number of MAP2-positive neurons was seen in the pres-
ence of htt-130Q infected astrocytes (Fig. 8 C). Because
cultured neurons normally start to express NMDA receptors at
7–8 d in vitro (DIV), we added MK801 to block glutamate re-
ceptors. MK801 (10 
 
 
 
M) significantly increased the number of
MAP2-positive neurons (Fig. 8 D and Fig. S4 [available at http://
www.jcb.org/cgi/content/full/jcb.200508072/DC1]), also sug-
gesting that mutant htt in cultured glia can promote neuronal
glutamate excitotoxicity in vitro.
Figure 8. Htt-mediated neurotoxicity in glia–
neuron coculture. (A) Cultured cortical neurons
were infected with adenoviral htt-23Q or htt-
130Q for 24 h. The infected neurons were
then cultured with or without wild-type glial
cells or MK801 (10  M) and labeled by anti-
bodies to htt (top), MAP2 (middle), and
Hoechst (bottom). Htt-130Q–infected neurons
show decreased MAP2-staining (arrows). (B)
The percentage of MAP2-positive neurons and
apoptotic neurons with nuclear DNA fragmen-
tation in the presence or absence of wild-type
glial cells or MK801. (C) Cultured glial cells
(4–6 wk) infected with adenoviral htt-23Q or
htt-130Q were cocultured with wild-type cor-
tical neurons. EM48 immunofluorescence
staining of glia–neuron coculture shows that
htt-23Q  is distributed in the cytoplasm
whereas htt-130Q accumulates in the nuclei
(arrows) of infected glial cells. The size of nu-
clei of cultured glial cells is often larger than
that of cultured cortical neurons. There is a de-
crease in the number of MAP2-positive neu-
rons in the coculture with htt-130Q–infected
glial cells. Nuclei were stained with Hoechst
(blue). (D) The percentage of MAP2-positive
neurons and apoptotic cells in the presence of
adenoviral infected glial cells. Neurons were
treated with or without MK801 (10  M). The
data (mean   SEM) were obtained by count-
ing the number of degenerated cells and the
total number of nuclei per image. **, P  
0.01 compared with neurons cocultured with
glial cells. Bars, 10  m. 
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To assess the specific protective effect of astrocytes in
the removal of extracellular glutamate from the medium, we
placed astrocytes, which were cultured on coverslips, on the
top of neuronal cells without direct contact during 1 h stimula-
tion with glutamate or NMDA. The astrocytes were removed
after stimulation, and neurons were cultured in the absence of
astrocytes for 24 h. Stimulation of 15–17 DIV striatal neurons
with 0.1 mM glutamate in the absence of astrocytes led to a
marked reduction in MAP2-positive neurons, whereas the
presence of wild-type astrocytes significantly increased the
number of MAP2-positive neurons (Fig. 9, A, B, and D). This
glial protection was diminished by the glutamate transporter
blockers (Fig. S5, available at http://www.jcb.org/cgi/content/
full/jcb.200508072/DC1). NMDA (0.4 mM), whose neuronal
toxicity is independent of glutamate transporters, elicited a
similar reduction of MAP2-positive neurons in the absence or
presence of astrocytes (Fig. 9, B and E). Also, cultured neu-
rons were more sensitive to glutamate (0.1 mM) than to
NMDA (0.4 mM; Fig. 9 A). Thus, this coculture system al-
lowed us to specifically examine the ability of glial cells to
remove extracellular glutamate and to protect neurons from
glutamate excitotoxicity.
We observed that wild-type astrocytes could protect
 
 
 
78% of cortical neurons from glutamate toxicity, whereas
HD astrocytes from R6/2 mice provided significantly less pro-
tection (43%). Similar results were also seen in cultured striatal
neurons, though striatal neurons were more sensitive than
cortical neurons to glutamate toxicity (Fig. 9 D). The increased
neuronal excitotoxicity by R6/2 astrocytes is apparently related
to glutamate transporters, as NMDA did not cause a significant
Figure 9. Reduced glial protection against
glutamate excitotoxicity by mutant htt in R6/2
astrocytes. (A) Cultured rat striatal neurons
(15–17 DIV) were stimulated for 1 h with
glutamate (0.1 mM) or NMDA (0.4 mM) in
the absence ( glia) or presence ( glia) of
wild-type rat cortical astrocytes. The astrocytes
were removed after the stimulation. Glutamate
stimulation caused neurons to degenerate and
lose MAP2 staining. Wild-type astrocytes in-
creased MAP2-positive neurons following
glutamate (0.1 mM), but not NMDA (0.4 mM)
stimulation, suggesting a specific protection
resulting from their glutamate uptake. (B) Cul-
tured astrocytes from littermate control ( WT
glia) mouse cortex also protected against
glutamate neuronal toxicity. Cultured astro-
cytes from R6/2 ( HD glia) mouse cortex,
however, showed a decrease in protection
against glutamate (0.1 mM), but not NMDA
(0.4 mM), toxicity. (C) Cultured R6/2 astro-
cytes contained GFAP (green) in the cyto-
plasm and mutant htt (red) in their nuclei but
had normal nuclear morphological appear-
ance (blue). (D) The percentage of MAP2-
positive  striatal or cortical neurons after
glutamate stimulation in the absence (No glia)
or presence of wile type ( WT glia) or R6/2
( HD glia) astrocytes. (E) The percentage of
MAP2-positive striatal neurons after NMDA
stimulation. The control is the number of cells
without excitotoxin stimulation. The data
(mean   SEM) were obtained from four to five
independent coculture experiments. *, P  
0.05; *, P   0.01 as compared with WT as-
trocytes. Bars: (A and B) 20  m; (C) 5  m.EXPRESSION OF HUNTINGTIN IN GLIAL CELLS • SHIN ET AL. 1009
difference in the number of MAP2-positive neurons between
cocultures with wild-type or R6/2 astrocytes (Fig. 9, B and E).
Examination of cocultured astrocytes verified that they ex-
pressed intranuclear aggregated htt but retained a normal nu-
clear appearance (Fig. 9 C). These results support the idea that
mutant htt in glial nuclei affects the expression of glutamate
transporters, leading to reduced protection against glutamate
neuronal excitotoxicity. 
Discussion
Expression of mutant htt in glial cells
The present findings suggest that mutant htt in glial cells can
contribute to neuronal dysfunction and excitotoxicity in HD
brains. Detection of the expression of mutant htt in glial cells
seems to depend largely on the antibodies used, as the previous
study with different antibodies did not identify glial htt aggre-
gates (Davies et al., 1997). Also, the small size and irregular
shape of glial cells made it difficult to identify nuclear htt in
these cells. EM48 sensitively detects mutant htt and its aggre-
gates (Li et al., 2000), allowing us to demonstrate the presence
of nuclear htt in glial cells in HD mouse brains. We also demon-
strated that cultured astrocytes isolated from R6/2 mouse brains
contain nuclear aggregates, consistent with a previous report
that cultured glia from a different exon1 htt transgenic mouse
model express nuclear htt (Martin-Aparicio et al., 2002). Because
HD mice (R6/2) expressing small NH2-terminal htt fragments
show more glial cells (up to 52.6% in white matter at 12 wk)
containing nuclear htt aggregates than Hdh CAG knock-in
mice, NH2-terminal mutant htt seems to be able to accumulate
in the nuclei of glial cells. HD mice display some early HD neu-
ropathology in the absence of obvious neurodegeneration. Thus,
study of the expression of mutant htt in glial cells in HD mice is
important for understanding the role of glial htt in early HD
pathology. We also observed htt aggregates in the nuclei of
 12.3% of GFAP-positive cells in postmortem brains of patients
with late-stage HD. This number might be underestimated be-
cause it did not include cells that express soluble mutant htt and
was obtained from the limited number of grade-3 HD patient
brains. Further quantitative investigation of the expression of
mutant htt in glial cells in HD patient brains, especially those at
early disease stages, remains to be performed.
Mutant htt and glial dysfunction
Whereas nuclear htt aggregates reflect the accumulation of
mutant htt in cells, soluble mutant htt can also affect cellular
function. An important question is whether mutant htt affects
glial function. Because glutamate excitotoxicity is thought to be
an important mechanism in HD pathology and astrocytes can
prevent this excitotoxicity, we focused on the effect of mutant
htt on glutamate uptake in astrocytes. Among the five known
glutamate transporters (GLT-1, GLAST, EAAC1, EAAT4, and
EAAT5), GLT-1 and GLAST are primarily expressed in astro-
cytes and seem to be the predominant glutamate transporters in
the brain (Maragakis and Rothstein, 2001). Although previous
studies have revealed that GLT-1 is decreased in HD mouse
brains (Lievens et al., 2001; Behrens et al., 2002), it remains
unclear how GLT-1 expression is altered and whether glial htt
affects neuronal viability. Using cultured astrocytes, we have
provided direct evidence that mutant htt in glial cells reduces the
expression of GLT-1 and GLAST. Also, dBcAMP-mediated ex-
pression of GLT-1 and, to a lesser extent, GLAST was impaired
by mutant htt. This reduction does not appear to be caused by an
altered dBcAMP stimulation by mutant htt, as dBcAMP-medi-
ated up-regulation of GFAP is not impaired. The promoters of
the GLT-1 and GLAST genes contain Sp1-binding sites (Su et
al., 2003). Considering that mutant htt binds Sp1 (Dunah et al.,
2002; Li et al., 2002), it is possible that Sp1-mediated expression
of GLT-1 and GLAST is affected by intranuclear htt. However,
in vivo glia–neuron interaction may counteract the inhibitory
effect of mutant htt on the expression of GLAST and thereby
minimize the reduction of GLAST in HD brains.
Although electron microscopy in the present study identi-
fied degenerating glial cells in HD mouse brains, the number of
degenerating glial cells is not substantive. Also, overexpression
of NH2-terminal mutant htt did not cause obvious death of cul-
tured glial cells in vitro. Thus, glial dysfunction may be more
important for neuronal toxicity than glial degeneration. In fact,
the expression of glutamate transporters and glutamate uptake
are reduced in HD mouse brains and cultured astrocytes with-
out degeneration. 
Glial htt and neuropathology
Unlike cultured glial cells, cultured neurons are vulnerable to
transfected NH2-terminal mutant htt (Saudou et al., 1998). How-
ever, when neurons that express full-length mutant htt are cul-
tured with glial cells, they do not show increased vulnerability
to glutamate excitotoxicity (Snider et al., 2003). The intracellu-
lar accumulation of NH2-terminal mutant htt fragments may be
required for neuronal htt toxicity, and the neurons may be pro-
tected from this toxicity by glial and other cells. Transgenic
mice that express exon-1 mutant htt in many types of cells in the
brain show obvious neuropathology and neurological symptoms
(Davies et al., 1997; Gu et al., 2005). In contrast, transgenic
mice expressing the same mutant htt only in cortical neurons do
not have obvious neuropathology and phenotypes, leading to
the idea that cell–cell interactions play an important role in HD
pathology (Gu et al., 2005). The present study shows that neuro-
degeneration caused by overexpressed NH2-terminal mutant htt
in vitro is reduced in the presence of glial cells.
A more interesting question is whether mutant htt affects
glial function to contribute to neuropathology. We found that
NH2-terminal mutant htt in glia promoted the death of cultured
neurons that did not express mutant htt. Mutant htt may affect
various functions of glial cells, including their production of
chemokines and neurotrophic factors. While this possibility re-
mains to be explored, the coculture system allowed us to detect
the specific effect of removal of extracellular glutamate by glia
on neurotoxicity (Fig. 9). 
Glial htt and the selective vulnerability of 
MSNs
MSNs constitute 70–80% of the total number of human striatal
neurons and receive glutamatergic afferents from all areas ofJCB • VOLUME 171 • NUMBER 6 • 2005 1010
the neocortex, thalamus, and limbic system (Parent and Hazrati,
1995). The specific composition of NMDA receptor subunits
could also underlie the hypersensitivity of MSNs to glutamate
excitotoxicity (Landwehrmeyer et al., 1995; Kuppenbender et
al., 2000; Li et al., 2003). In addition, mutant htt in MSNs is
found to increase their sensitivity to NMDA in brain slices by
modulating the activity or expression of glutamate receptor
subunits (Cepeda et al., 2001; Li et al., 2003). All of these char-
acteristics make MSNs highly vulnerable to glutamate stimula-
tion. Thus, although NH2-terminal mutant htt may affect GLT-1
expression and glutamate uptake in various brain regions, the
impairment of extracellular glutamate removal in the stria-
tum could particularly increase the vulnerability of MSNs to
glutamate excitotoxicity. Impaired glial glutamate uptake in
R6/2 mice may also significantly increase extracellular glu-
tamate concentration in the brain (Lievens et al., 2001; Beh-
rens et al., 2002), which, in turn, would raise the threshold of
neuronal response to excitotoxins so that neurons in R6/2
mouse brain are less responsive to exogenously administered
NMDA agonists (Hansson et al., 2001).
Conclusion
Glial dysfunction is known to contribute to other neurodegener-
ative diseases, and wild-type nonneuronal cells can ameliorate
motor neuron degeneration in a mouse model of amyotrophic
lateral sclerosis (Clement et al., 2003). In addition to its effect
on glial nuclei, mutant htt in neurons can cause multiple dys-
functions (Li and Li, 2004) including transcriptional dysregula-
tion and impaired transport (Gunawardena et al., 2003). Mutant
htt in neurons and glia can independently or synergistically
affect neuronal function depending on its subcellular accumu-
lation in these cells during disease progression. This study
underscores the importance of glial protection against neurode-
generation caused by misfolded polyQ proteins and also pro-
vides a new avenue for studying the pathogenesis of other
polyQ diseases in which the disease proteins may also be ex-
pressed in glial cells.
Materials and methods
Reagents
R6/2 mice and Hdh CAG(150) knock-in mice, which express a 150Q
repeat, were bred and maintained in the animal facility at Emory University
under specific pathogen-free conditions in accordance with institutional
guidelines. Postmortem brain samples of patients with HD or AD were pro-
vided by the Harvard Brain Tissue Resource Center. The brain samples
were from three female HD patients. Their ages of death were 57
(B5295), 65 (B5297), and 39 (B5299). The postmortem intervals were
18, 25, and 24 h, respectively. The pathological severity of these cases is
grade-3, and expanded CAG repeats are 41–47 units. AD patients were
female cases (B4842 and B5092) at 61 and 67 yr of age with postmor-
tem interval 6.75 and 27 h, respectively.
Rabbit polyclonal antibody (EM48) and mouse monoclonal anti-
bodies (mEM48) against the NH2-terminal region (amino acids 1–256) of
human huntingtin were described in our previous study (Li et al., 2002).
Rabbit antibody against GLT-1 (cGLT T88) was provided by J. Rothstein
(Johns Hopkins University, Baltimore, MD). Rabbit antibody to GLAST was
provided by K. Tanaka (Tokyo Medical and Dental University, Tokyo, Ja-
pan) and Gi. Bonvento (CEA CNRS, Orsay, France). Other antibodies
used included mouse monoclonal antibodies against polyglutamine (1C2)
and GFAP (Chemicon), MAP2 (AP20; BD Biosciences), monoclonal  -tubulin
(Sigma Aldrich), GLAST (Chemicon), and anti–mouse or –rabbit antibodies
conjugated with Alexa Fluor 488 (Invitrogen). Antibodies to myelin basic
protein (1:500; Chemicon) and a microglial protein (F4/80 1:100, Sero-
tec/Biozol) were also used.
Immunocytochemistry and Western blotting
Electron microscopy was performed as described previously (Li et al.,
2000). For Immunofluorescence light microscopy, brains of R6/2 and lit-
termate control mice were rapidly isolated and cut to sections (8–10  m)
with a cryostat at  20 C. The brain sections were placed on gelatin-pre-
coated glass slides. Mouse and human brain sections were examined with
immunofluorescence labeling as described previously (Li et al., 2000;
Zhou et al., 2003). Light micrographs were taken using a microscope
(Axiovert 200 MOT; Carl Zeiss MicroImaging, Inc.) and a 63  lens
(LD-Achroplan 63 /0.75) with a digital camera (Orca-100; Hamamatsu)
and the Openlab software (Improvision Inc). To count glial cells containing
htt aggregates in HD mouse brains, random images (five to eight) of white
matter or other brain regions in each brain section were captured using LD
plan-neofluar lens (20 /0.4 or 40 /0.6) and stored in a computer for
counting. Glial cells (15–60) in each image were counted. To examine
HD patient brains, we studied three cases of HD patient brains and
counted 1,004 GFAP-positive cells in four independent immunocytochemi-
cal experiments. AD patient brain samples were used as the control. Con-
focal image analysis was performed with a confocal microscope system
(LSM 510 NLO; Carl Zeiss MicroImaging, Inc.).
For Western blots, cultured cells or brain tissues were solubilized in
1% SDS, and then resuspended in SDS sample buffer and sonicated for
10 s. The total lysate was used for Western blotting with the ECL kit (Amer-
sham). RT-PCR to examine the transcripts of GLT-1 and GLAST was per-
formed using the same oligonucleotide primers and methods as described
previously (Tortarolo et al., 2004). Oligonucleotide primers for GLAST
cDNA and actin were included in the same reaction for amplification with
21 cycles, whereas GLT-1 cDNA was amplified alone with 23 cycles
because its PCR products had a molecular weight similar to that of actin.
Adenoviral vector construction and preparation
Recombinant adenoviruses were generated according to a previously re-
ported protocol (He et al., 1998). Human htt cDNAs coding the first 208
amino acid plus an additional 23 or 130 glutamine repeats were fused in-
frame to GFP COOH-terminal cDNA, resulting in GFP-htt fusion proteins
containing a 23- (htt-23Q) or 130 (htt-130Q)-glutamine repeat that were
expressed under the control of a cytomegalovirus (CMV) promoter. The vi-
ral titer was determined by measuring the number of infected HEK293
cells expressing GFP. All viral stocks were adjusted to 10
9 VP/ml before
their use.
Glial and neuronal cultures
Enriched glial cultures were prepared from 1 to 2 d postnatal rat or mouse
pups. Microglia cells were dissociated from the culture after shaking cul-
tured glial cells or enriched for culture. Immunostaining with antibodies to
specific makers (GFAP for astrocytes, F4/80 for microglia, and myelin ba-
sic protein for oligodendrocytes) was used to identify different types of glial
cells. Cultured astrocytes were treated with 0.25 mM dBcAMP for 7–10 d
to increase the expression of glutamate transporters (Eng et al., 1997).
For neuronal culture, mixed neuronal–glial cultures were prepared
from the cerebral cortex and striatum of rat fetuses at embryonic day
17–18. Viable cells were plated at 1   10
6 cells/ml on poly-D-lysine–
coated plastic culture plates (Corning Costar) in B27-supplemented
Neurobasal medium (Invitrogen). To reduce glial proliferation, we
added cytosine arabinoside to the cultures 3 d after plating (5   10
6 M
final concentration). At 7–8 DIV, the majority of cells were mature neurons
with elongated processes, and they were used for viral infection. In some
experiments, neurons were treated with cytosine arabinoside for 6–7 d, and
then MK801 (10  M) for 30 min. Cultured neurons were then infected with
or without adenoviral vectors for 24 h. After washing, infected neurons
were cocultured with wild-type glial cells that were on coverslips for 3 d.
For glia–neuron coculture, we first infected astrocytes (4–6 wk) from
rat brain cortex with adenoviral GFP, htt-23Q, or htt-130Q for 24 h. After
washing, we then isolated cortical or striatal neurons and plated them on
the top of infected astrocytes and cultured these neurons in B27-supple-
mented neurobasal medium. To inhibit the proliferation of newly added
glial cells, 2.5   10
6 M cytosine arabinoside was added 1 d after plating
neurons. The newly isolated glial cells were unable to grow because serum
free media and cytosine arabinoside suppressed their growth. Neurons co-
cultured with infected astrocytes for more than 4 d were then examined.
For neuronal–glial coculture treated with glutamate or NMDA, corti-
cal or striatal neurons (DIV 14–17) were cocultured with glial cells that
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rons without direct contact. The coverslips were placed over the cultured
neurons during stimulation with glutamate or NMDA in B27-supplemented
neurobasal medium for 1 h at 37 C. This glial protection was verified by us-
ing the glutamate transporter blockers DHK and threo- -benzyloxyaspartate.
After stimulation, the glial cells on the coverslips were removed, and the
medium was changed to fresh drug-free medium. The treated neurons
were cultured for 24 h before immunofluorescent examination.
Glutamate uptake assay
Cortico-striatal brain slices (400  m, three pieces/brain) from R6/2 and
littermate controls at the age of 4–5 or 10–12 wk (four animals per
group) were prepared with vibratome. The slices were placed in ice-cold
artificial CSF (aCSF) ([mM] 118 NaCl, 4.8 KCl, 2.6 CaCl2, 1.2
MgSO4, 25 NaHCO3, and 1.2 KH2PO4, 11 glucose, 0.6 ascorbic acid)
with aeration of 95% O2 5% CO2. Half of a slice was preincubated
with 1 mM dihydrokainate (DHK; Sigma Aldrich) for 1 h at 37 C, and
the other half was preincubated without DHK treatment. After preincuba-
tion, [
3H]L-glutamate was added into solution at a final concentration of
25 nM and incubated for 15 min. The incubation was terminated by
rapidly removing the solution, and the slices were washed with 4 ml of
ice-cold aCSF buffer three times. Slices were lysed in 0.1% NaOH with
sonication, and the radioactivity was determined using a liquid scintil-
lation counter. Protein amount of brain slices was measured to nor-
malize counting results. The differences between DHK treated and non-
treated samples were obtained to reflect GLT-1–specific glutamate uptake
(nmol/mg protein/15 min).
For glutamate uptake assay of cultured astrocytes, glial cells preincu-
bated with 10 mM unlabeled glutamate served as a control to obtain a back-
ground value. Vmax and Km were determined from Eadie-Hofstee plots.
Neuronal degeneration and cell viability assays
Degenerated neurons were identified by their disrupted or reduced neu-
rites and condensed or fragmented nuclear DNA using the same method
as described previously (Saudou et al., 1998). Cultured neurons were
fixed and stained with antibody to MAP2 antibody for neuronal cells and
Hoechst for nuclear DNA. Fluorescent images were captured and neu-
rons with normal or degenerating morphology were counted. To count
cells after immunocytochemistry, 10–20 pictures of each experimental
group were taken with a 20  objective (Carl Zeiss MicroImaging,
Inc.). The imaged areas were chosen randomly from at least three dif-
ferent wells per experimental group. The controls were neurons that
had not been treated with excitotoxins. The numbers of MAP2-positive
neurons and apoptotic neurons were expressed as the percentage of
total neurons counted. Data were obtained from 4–5 independent co-
culture experiments.
The viability of glial cells was determined by a modified MTT assay
using a microplate reader (SPECTRAmax Plus; Li et al., 2002). The absor-
bance at 490 nm was normalized with the amount of cellular protein used
for the assay in a 100- l reaction.
Statistical analysis
Statistical significance was assessed by using Student’s t test or two-way
ANOVA test followed by Bonferroni post-hoc analysis. Calculations were
performed by SigmaPlot 4.11 and Prism (version 4) software. Statistical
significance was taken to be P   0.05.
Online supplemental material
Fig. S1 shows electron micrographs of R6/2 mouse brain containing de-
generated neurons and glial cells. Fig. S2 shows an age-dependent in-
crease of glial cells containing intracellular mutant htt in R6/2 mice. Fig.
S3 shows Western blot analysis of glutamate transporters in R6/2 and HD
knock-in mouse brains. Fig. S4 shows that MK801 reduced neurotoxicity
in the presence of glial cells expressing mutant htt. Fig. S5 shows that glial
protection was inhibited by glutamate transporter blockers. Video 1 shows
three-dimensional images of a GFAP-positive astrocyte containing htt aggre-
gates in its nucleus. Online supplemental material is available at available
at http://www.jcb.org/cgi/content/full/jcb.200508072/DC1.
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